Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘NASDAQ:TRVN’

people, person, lab, nuclear, hydrogen, concept, chemistry, technicians, researching, formula, chemists, biotechnology, researchers, discovery, weapon, samples,

Is Trevena Inc (TRVN) A Good Stock To Buy?

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors......(read more)
lab, laboratory, clinic, clinical, scientist, researching, research, chemist, medical, man, male, specialist, focus, chemistry, test, science

Trevena Inc (TRVN) Just Got Its Billion Dollar Pain Management Bid Underway

Trevena Inc (NASDAQ:TRVN) just kicked off a two concurrent phase III pivotals in its lead pain management candidate, Oliceridine. The trials are set to......(read more)
17 Most Drug Addicted Countries in the World in 2017

Why Are These Stocks Making Headlines Today?

Although crude futures have rallied by over 2% and the Dow Jones is 100 points higher today, shares of Aduro BioTech Inc (NASDAQ:ADRO), Trevena Inc (NASDAQ......(read more)
Andrey_Popov/Shutterstock.com

What Do Hedge Funds Think of Trevena Inc (TRVN)?

Insider Monkey finished processing more than 700 13F filings made by hedge funds and prominent investors. These filings show these funds’ portfolio......(read more)
100727-N-6410J-037

Positive Study Results Have This Company’s Shares Up By More Than 70% Today

The shares of Trevena Inc (NASDAQ:TRVN) are up by over 70% after the clinical-stage biopharmaceutical company revealed positive phase 2b study results......(read more)
Peter Kolchinsky

Regulus Therapeutics Inc (RGLS), Trevena Inc (TRVN), Juno Therapeutics Inc (JUNO): RA Capital’s Top New Biotech Picks

Peter Kolchinsky’s RA Capital Management filed its latest 13F with the Securities and Exchange Commission in February, and we’ve gone through the......(read more)